Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies

AAPS Journal

Volumn 19, Issue 4, 2017, Pages 1136-1147

  Wojciechowski, Jessica ^a   Upton, Richard N ^a,b   Mould, Diane R ^b   Wiese, Michael D ^a   Foster, David J R ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Projections Research Inc   (United States)

Author keywords

Bayesian; dosing; infliximab; pharmacokinetics; pharmacometrics

Indexed keywords

ALBUMIN; DRUG ANTIBODY; INFLIXIMAB; GASTROINTESTINAL AGENT;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BAYES THEOREM; BODY WEIGHT; CHILD; COMPUTER MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG MONITORING; DRUG RESPONSE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; COMPUTER SIMULATION; DOSE RESPONSE;

COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB;

EID: 85018715830     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-017-0082-8     Document Type: Article

References (28)

1. Australian Medicines Handbook 2016. Rossi S, editor. Adelaide: Australian Medicines Handbook Pty Ltd; 2016.
2. Janssen Biotech Inc. Remicade: Highlights of Prescribing Information. 2013 Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf
3. Peyrin-Biroulet L, Deltenre P, De Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–53.
4. Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohn’s Colitis. 2013;7(9):736–43.
5. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–46.
6. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou G, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2014:gutjnl-2014-307883.
7. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9. e3.
8. Drobne D, Bossuyt P, Breynaert C, Cattaert T, Casteele NV, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants W-J. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(3):514–21. e4
9. Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296–307. e5
10. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003.
11. Mould D, D’Haens G, Upton R. Clinical decision support tools: the evolution of a revolution. Clin Pharmacol Ther. 2016;99(4):405–18.
12. Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26(3):294–305.
13. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci. 1982;71(12):1344–8.
14. Mould DR, Upton RN, Wojciechowski J. Dashboard systems: implementing pharmacometrics from bench to bedside. AAPS J. 2014;16(5):925–37.
15. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.
16. Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.
17. Wickham H. The split-apply-combine strategy for data analysis. J Stat Softw. 2011;40(1):1–29.
18. Baron KT, Hindmarsh AC, Petzold LR, Gillespie B, Margossian C, Metrum Research Group LLC. mrgsolve: simulation from ODE-based population PK/PD and systems pharmacology models. R package version 0.6.1.9000. http://metrumrg.com/opensourcetools.html
19. Beal S, Sheiner LB, Boeckmann A, Bauer RJ, Sheiner LB, Boeckmann A, Bauer RJ,NONMEM User’s Guides. (1989–2009), Icon Development Solutions, Ellicott City, MD, USA, 2009
20. Xu Z, Mould D, Hu C, Ford J, Keen M, Davis H, Zhou H. Population pharmacokinetic analysis of infliximab in pediatrics using integrated data from six clinical trials. Clin Pharmacol Drug Dev. 2012;1:203.
21. Rosen M, Minar P, Vinks A. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41(11):1094–103.
22. Weeke B, Jarnum S. Serum concentration of 19 serum proteins in Crohn’s disease and ulcerative colitis. Gut. 1971;12(4):297–302.
23. Brandse JF, Strik AS, Mould D, Ashruf Y, Smeekes OS, Kuin S, van den Brink G, D’Haens GR. Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBD. Gastroenterology. 2016;150(4):S144.
24. Papamichael K, Van Stappen T, Casteele NV, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(4):543–9.
25. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–54.
26. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71.
27. Wojciechowski J, Hopkins AM, Upton RN. Interactive pharmacometric applications using R and the shiny package. CPT: Pharmacometrics & Systems pharmacology. 2015;4(3):1–14.
28. RStudio Inc. shiny: Web Application Framework for R. R package version 0.13.2. http://cran.r-project.org/package=shiny